Cue Biopharma (CUE) AI Stock Analysis

• Market Cap: $55.42M
• Dividend Yield: N/A
• Average Volume (3M): 238.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.68
• Revenue Growth: -0.11%
• EPS Growth: 43.47%
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 76,845,900
• 10 Day Avg. Volume: 365,762
• 30 Day Avg. Volume: 238,588
• PEG Ratio: 0.04
• Price to Book (P/B): 3.51
• Price to Sales (P/S): 6.61
• P/FCF Ratio: -1.69
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 5.46
• Enterprise Value/Gross Profit: 5.53
• Enterprise Value/Ebitda: -1.24
• 1Y Price Target: $4.00
• Price Target Upside: 488.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.50 ▼(-26.47% Downside)

Cue Biopharma's overall stock score is heavily impacted by its weak financial performance, characterized by ongoing losses and cash flow issues. Technical analysis further indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio. These factors collectively suggest significant risks for investors.

Positive Factors

Innovative Platform

The Immuno-STAT™ platform allows selective modulation of T cell responses, providing a competitive edge in developing targeted therapies for cancer and autoimmune diseases.

Collaborative Business Model

Collaborations with larger pharmaceutical firms enable Cue Biopharma to leverage its technology while sharing financial risks, enhancing its long-term growth potential.

Potential Revenue from Clinical Trials

Advancing clinical programs and successful trials can significantly boost revenue through product sales and royalties, supporting long-term financial health.

Negative Factors

Negative Cash Flow

Ongoing cash burn and negative cash flows challenge liquidity and financial stability, requiring strategic improvements in cost management and operational efficiency.

Profitability Challenges

Significant profitability challenges due to high operating losses indicate inefficiencies in cost management, impacting long-term financial sustainability.

Persistent Losses

Consistent financial losses undermine the company's ability to generate profits, necessitating strategic improvements to ensure future financial health.

Cue Biopharma Business Overview & Revenue Model

Company Description

Cue Biopharma, Inc. is an innovative biotechnology company focused on developing biologic therapies to harness the power of the immune system to treat cancer and autoimmune diseases. The company operates in the biopharmaceutical sector and specializes in its proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, which enables the selective modulation of T cell responses to target specific disease mechanisms. Cue Biopharma's core products include its clinical-stage therapies, which are designed to enhance immune responses against tumors while minimizing off-target effects.

How the Company Makes Money

Cue Biopharma generates revenue primarily through a combination of research and development collaborations, licensing agreements, and potential milestone payments from partnerships with pharmaceutical companies. The company may also receive funding through grants and investments aimed at advancing its clinical programs. By collaborating with larger pharmaceutical firms, Cue Biopharma can leverage its unique technology platform while sharing the financial risks associated with drug development. Additionally, successful clinical trials can lead to revenue generation through product sales, royalties, and further licensing agreements as therapies progress through various stages of development.

Cue Biopharma Financial Statement Overview

Summary

Cue Biopharma faces significant financial challenges with persistent losses and negative cash flows. Despite some revenue growth, profitability and cash generation are under pressure. The balance sheet shows moderate leverage, but negative return on equity and ongoing cash burn pose risks to financial stability.

Income Statement

Cue Biopharma's income statement reveals significant challenges in profitability, with negative net profit margins and EBIT margins over the TTM period. Although there is a slight revenue growth, the company struggles with high operating losses, indicating inefficiencies in cost management. The gross profit margin is relatively high, suggesting potential for improvement if operational costs are controlled.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating manageable leverage. However, the negative return on equity highlights the company's inability to generate profits from shareholders' investments. The equity ratio is stable, but the overall financial health is weakened by consistent losses.

Cash Flow

Cash flow analysis indicates negative operating cash flow and free cash flow, reflecting ongoing cash burn. The free cash flow to net income ratio is slightly above 1, suggesting that cash outflows are closely aligned with net losses. The company faces challenges in generating positive cash flows, which could impact its liquidity position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.29M	9.29M	5.49M	1.25M	14.94M	3.15M
Gross Profit	8.19M	9.29M	-32.61M	-560.83K	16.72M	-30.39M
EBITDA	-36.42M	-37.53M	-46.05M	-50.49M	-45.44M	-43.99M
Net Income	-38.90M	-40.67M	-50.73M	-52.80M	-44.16M	-44.78M
Balance Sheet
Total Assets	40.71M	32.19M	61.53M	91.28M	83.40M	99.53M
Cash, Cash Equivalents and Short-Term Investments	27.49M	22.46M	48.51M	76.29M	64.37M	84.87M
Total Debt	7.63M	8.88M	14.70M	19.32M	12.02M	7.15M
Total Liabilities	22.55M	14.69M	24.45M	25.60M	17.91M	20.62M
Stockholders Equity	18.16M	17.50M	37.09M	65.68M	65.49M	78.91M
Cash Flow
Free Cash Flow	-28.32M	-36.40M	-39.96M	-41.98M	-39.75M	-33.09M
Operating Cash Flow	-28.14M	-36.33M	-39.96M	-41.81M	-38.84M	-32.49M
Investing Cash Flow	-80.00K	32.00K	25.00M	-24.61M	9.11M	4.46M
Financing Cash Flow	25.69M	10.24M	11.86M	53.66M	19.23M	58.61M

Cue Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUE, the sentiment is Negative. The current price of 0.68 is below the 20-day moving average (MA) of 0.75, below the 50-day MA of 0.75, and below the 200-day MA of 0.85, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 39.56 is Neutral, neither overbought nor oversold. The STOCH value of 18.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CUE.

Cue Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MAIA	44 Neutral	$36.29M	-1.86	-2691.06%	―	―	44.50%
CUE	41 Neutral	$55.42M	-1.31	-195.55%	―	-0.11%	43.47%
ALGS	38 Underperform	$44.35M	-0.36	-141.82%	―	-55.88%	6.14%
CELU	38 Underperform	$45.91M	-0.54	-6367.24%	―	4.45%	45.19%
ACRV	36 Underperform	$59.14M	―	-47.87%	―	―	18.86%

Cue Biopharma Corporate Events

Cue Biopharma Partners with ImmunoScape for Cell Therapy

On November 6, 2025, Cue Biopharma and ImmunoScape announced a strategic collaboration to develop a novel cell therapy approach for solid tumors. This agreement allows ImmunoScape to research, develop, and commercialize molecules from Cue Biopharma’s CUE-100 Series, aiming to advance a ‘Seed-and-Boost’ immunotherapy approach. The collaboration is expected to enhance Cue Biopharma’s focus on autoimmune disease programs and advance its Immuno-STAT platform in oncology, potentially providing a breakthrough in T cell therapy with improved efficacy and tolerability. Cue Biopharma will receive significant financial benefits, including equity in ImmunoScape and royalties from future sales.

The most recent analyst rating on (CUE) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.

Cue Biopharma Appoints Usman Azam as New CEO

On September 26, 2025, Cue Biopharma announced the appointment of Usman Azam as the new President and CEO, effective September 29, 2025, succeeding Daniel R. Passeri who will retire but remain as a strategic advisor. Dr. Azam’s extensive experience in leading biopharmaceutical companies is expected to enhance Cue Biopharma’s strategic direction and operational capabilities, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (CUE) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.

Cue Biopharma’s Q2 2025: Strategic Advances and Financial Highlights

Cue Biopharma, Inc., based in Boston, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing innovative biologics to selectively engage and modulate disease-specific T cells for treating autoimmune diseases and cancer. The company’s proprietary Immuno-STAT® platform aims to harness the immune system’s potential without adverse systemic effects.